From the Food and Drug Administration.
D019386:Alendronate; D002986:Clinical Trials as Topic; D004164:Diphosphonates / Q000627:therapeutic use*; D017277:Drug Approval; D004635:Emergency Medicine; D028744:Ethics Committees, Research; D035082:Federal Government; D033161:Government Regulation; D006801:Humans; D007258:Informed Consent; D010001:Osteitis Deformans / Q000188:drug therapy; D010024:Osteoporosis / Q000188:drug therapy; D011367:Professional Staff Committees; D012106:Research; D035842:Research Subjects; D036302:Therapeutic Human Experimentation; D014481:United States; D014486:United States Food and Drug Administration
D004164:Diphosphonates; D019386:Alendronate